Deals Driving Oncology: ImmunoGen CEO Mark Enyedy on Biopharma’s Year Ahead
Cancer continues to reign in 2018 as the emperor of all maladies, with almost boundless opportunities for companies with a solid base in new science and a differentiated therapy set that can be tailored to the needs of individual patients not served by the current standard of care. ImmunoGen CEO Mark Enyedy tells In Vivo that there’s never been a better time for drugmakers in the oncology marketplace.
You may also be interested in...
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.